Rationale for intensive intravesical chemotherapy for superficial bladder cancer.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009366:Neoplasm Seeding; D009374:Neoplasms, Experimental / Q000188:drug therapy; D013713:Teniposide / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D008937:Mitomycins; D004317:Doxorubicin; D013852:Thiotepa; D013713:Teniposide